bupropion Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anorexics 435 34911-55-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bupropion
  • (+/-)-Bupropion
  • amfebutamon
  • amfebutamone
  • aplenzin
  • elontril
  • bupropion hydrochloride
  • bupropion hydrobromide
  • bupropion HCl
  • wellbutrin
A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
  • Molecular weight: 239.74
  • Formula: C13H18ClNO
  • CLOGP: 3.21
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 29.10
  • ALOGS: -3.54
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 312 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 31.28 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Dec. 30, 1985 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 9441.22 33.59 2064 5384 18970 2331667
Toxicity to various agents 3994.93 33.59 1148 6300 31606 2319031
Overdose 1425.90 33.59 469 6979 19438 2331199
Cardiac arrest 1306.71 33.59 410 7038 14520 2336117
Intentional overdose 1298.76 33.59 383 7065 10938 2339699
Seizure 1288.86 33.59 458 6990 24008 2326629
Cardio-respiratory arrest 1274.10 33.59 360 7088 8786 2341851
Poisoning 1036.45 33.59 241 7207 2579 2348058
Drug hypersensitivity 964.47 33.59 446 7002 46197 2304440
Respiratory arrest 894.35 33.59 251 7197 5927 2344710
Generalised tonic-clonic seizure 886.88 33.59 242 7206 5130 2345507
Suicide attempt 745.34 33.59 251 7197 11031 2339606
Hypotension 655.06 33.59 306 7142 32130 2318507
Drug abuse 644.78 33.59 229 7219 11797 2338840
Depression 619.63 33.59 282 7166 27850 2322787
Agitation 598.21 33.59 212 7236 10839 2339798
Nausea 595.47 33.59 444 7004 111745 2238892
Electrocardiogram QT prolonged 588.12 33.59 192 7256 7622 2343015
Electrocardiogram QRS complex prolonged 510.97 33.59 114 7334 988 2349649
Anxiety 503.89 33.59 248 7200 29111 2321526
Product substitution issue 478.03 33.59 148 7300 4921 2345716
Status epilepticus 475.91 33.59 126 7322 2352 2348285
Tremor 469.63 33.59 212 7236 20449 2330188
Drug ineffective 437.15 33.59 356 7092 101268 2249369
Headache 413.67 33.59 313 7135 79866 2270771
Serotonin syndrome 378.98 33.59 114 7334 3426 2347211
Suicidal ideation 375.13 33.59 151 7297 10936 2339701
Insomnia 372.25 33.59 194 7254 25593 2325044
Feeling abnormal 365.12 33.59 186 7262 23395 2327242
Dizziness 353.83 33.59 252 7196 58413 2292224
Tachycardia 342.98 33.59 159 7289 16250 2334387
Myoclonus 318.45 33.59 92 7356 2391 2348246
Vomiting 294.34 33.59 245 7203 71357 2279280
Somnolence 283.48 33.59 157 7291 23328 2327309
Mydriasis 274.69 33.59 80 7368 2139 2348498
Drug interaction 272.38 33.59 165 7283 28998 2321639
Coma 264.17 33.59 111 7337 8945 2341692
Therapeutic response unexpected 254.59 33.59 86 7362 3773 2346864
Pulseless electrical activity 250.15 33.59 63 7385 952 2349685
Product complaint 244.73 33.59 87 7361 4451 2346186
Exposure via ingestion 240.11 33.59 58 7390 730 2349907
Sinus tachycardia 238.79 33.59 79 7369 3246 2347391
Unresponsive to stimuli 227.51 33.59 84 7364 4792 2345845
Intentional product misuse 226.59 33.59 101 7347 9388 2341249
Loss of consciousness 214.12 33.59 121 7327 18646 2331991
Confusional state 212.47 33.59 132 7316 24212 2326425
Cardiogenic shock 210.64 33.59 67 7381 2424 2348213
Exposure during pregnancy 188.42 33.59 124 7324 25095 2325542
Urticaria 185.41 33.59 121 7327 24140 2326497
Irritability 181.39 33.59 77 7371 6350 2344287
Postmortem blood drug level increased 180.48 33.59 30 7418 32 2350605
Ventricular tachycardia 178.64 33.59 62 7386 2949 2347688
Bradycardia 172.51 33.59 85 7363 9896 2340741
Condition aggravated 170.74 33.59 128 7320 31851 2318786
Brain injury 158.63 33.59 43 7405 876 2349761
Hyperhidrosis 158.63 33.59 93 7355 15329 2335308
Areflexia 150.17 33.59 38 7410 585 2350052
Constipation 148.59 33.59 101 7347 21528 2329109
Fatigue 148.14 33.59 183 7265 84690 2265947
Temperature regulation disorder 145.85 33.59 29 7419 132 2350505
Mental status changes 144.73 33.59 63 7385 5519 2345118
Disorientation 133.61 33.59 62 7386 6310 2344327
Death 133.07 33.59 170 7278 81298 2269339
Weight increased 131.71 33.59 95 7353 22242 2328395
Hallucination 130.74 33.59 66 7382 8082 2342555
Cardiotoxicity 128.33 33.59 39 7409 1208 2349429
Feeling jittery 127.12 33.59 43 7405 1889 2348748
Metabolic acidosis 121.54 33.59 57 7391 5941 2344696
Food allergy 111.12 33.59 30 7418 601 2350036
Pupil fixed 110.69 33.59 28 7420 430 2350207
Palpitations 108.58 33.59 75 7373 16381 2334256
Heart rate increased 106.37 33.59 64 7384 11041 2339596
Abortion spontaneous 102.41 33.59 67 7381 13378 2337259
Aggression 101.66 33.59 47 7401 4739 2345898
Immunodeficiency 99.48 33.59 31 7417 1045 2349592
Coeliac disease 98.51 33.59 29 7419 803 2349834
Nervousness 98.03 33.59 47 7401 5142 2345495
Drug withdrawal syndrome 97.12 33.59 51 7397 6770 2343867
Crying 95.96 33.59 44 7404 4352 2346285
Lethargy 95.93 33.59 55 7393 8675 2341962
Dyskinesia 95.43 33.59 45 7403 4744 2345893
Hypersensitivity 94.79 33.59 80 7368 23513 2327124
Depressed level of consciousness 94.67 33.59 52 7396 7552 2343085
Dry mouth 93.38 33.59 53 7395 8200 2342437
Rash 91.90 33.59 121 7327 59437 2291200
Amnesia 91.40 33.59 50 7398 7203 2343434
Electroencephalogram abnormal 89.97 33.59 27 7421 800 2349837
Gait disturbance 89.65 33.59 76 7372 22469 2328168
Fall 89.11 33.59 106 7342 46993 2303644
Hallucination, visual 88.36 33.59 37 7411 2942 2347695
Disturbance in attention 88.10 33.59 45 7403 5640 2344997
Accidental overdose 87.46 33.59 40 7408 3932 2346705
Muscle rigidity 87.01 33.59 32 7416 1799 2348838
Tinnitus 86.47 33.59 43 7405 5092 2345545
Aphasia 85.16 33.59 42 7406 4886 2345751
Hepatic enzyme increased 82.42 33.59 52 7396 9750 2340887
Bursitis 82.09 33.59 31 7417 1877 2348760
Panic attack 81.37 33.59 38 7410 3918 2346719
Gastrointestinal sounds abnormal 81.25 33.59 23 7425 552 2350085
White blood cell count abnormal 80.62 33.59 24 7424 691 2349946
Circulatory collapse 80.46 33.59 37 7411 3683 2346954
Rash erythematous 80.32 33.59 43 7405 5933 2344704
Hyperreflexia 79.29 33.59 25 7423 876 2349761
Mental disorder 77.83 33.59 37 7411 3970 2346667
Product residue present 77.55 33.59 26 7422 1110 2349527
Brain death 76.94 33.59 22 7426 548 2350089
Poisoning deliberate 76.34 33.59 26 7422 1165 2349472
Restlessness 76.21 33.59 38 7410 4525 2346112
Withdrawal syndrome 74.71 33.59 34 7414 3303 2347334
Postictal state 74.07 33.59 18 7430 232 2350405
Memory impairment 73.89 33.59 54 7394 12869 2337768
Leukocytosis 72.46 33.59 34 7414 3542 2347095
Vertigo 72.00 33.59 47 7401 9337 2341300
Depressed mood 71.53 33.59 38 7410 5160 2345477
Vision blurred 69.96 33.59 55 7393 14613 2336024
Hypertension 69.67 33.59 72 7376 27289 2323348
Multiple fractures 69.59 33.59 21 7427 634 2350003
Abdominal pain upper 68.99 33.59 65 7383 22035 2328602
Abnormal behaviour 68.91 33.59 36 7412 4724 2345913
Respiratory depression 67.88 33.59 28 7420 2142 2348495
Akathisia 67.70 33.59 26 7422 1648 2348989
Migraine 66.59 33.59 47 7401 10606 2340031
Inappropriate schedule of product administration 65.29 33.59 49 7399 12155 2338482
Pain 63.83 33.59 104 7344 61753 2288884
Therapeutic product effect decreased 63.76 33.59 46 7402 10743 2339894
Hyperthermia 63.69 33.59 24 7424 1444 2349193
Pruritus 63.60 33.59 86 7362 43254 2307383
Arrhythmia 63.60 33.59 37 7411 5991 2344646
Acute respiratory distress syndrome 62.72 33.59 30 7418 3262 2347375
Hypoxia 62.48 33.59 37 7411 6190 2344447
Sleep-related eating disorder 61.99 33.59 14 7434 128 2350509
Asthma 61.80 33.59 46 7402 11268 2339369
Urinary incontinence 61.24 33.59 32 7416 4201 2346436
Malaise 60.81 33.59 96 7352 55489 2295148
Drug intolerance 60.22 33.59 49 7399 13668 2336969
Supraventricular tachycardia 59.73 33.59 25 7423 1984 2348653
Urinary retention 59.64 33.59 30 7418 3637 2347000
Pneumonia aspiration 59.07 33.59 30 7418 3712 2346925
Encephalopathy 58.99 33.59 32 7416 4529 2346108
Mood altered 58.40 33.59 27 7421 2719 2347918
Psychotic disorder 58.22 33.59 32 7416 4647 2345990
Dyspnoea 57.68 33.59 114 7334 78619 2272018
Delirium 57.60 33.59 33 7415 5190 2345447
Anger 57.56 33.59 26 7422 2481 2348156
Torsade de pointes 57.04 33.59 25 7423 2221 2348416
Blood pressure increased 56.94 33.59 52 7396 16934 2333703
Pulmonary oedema 56.77 33.59 37 7411 7326 2343311
Balance disorder 56.32 33.59 41 7407 9706 2340931
Major depression 56.22 33.59 20 7428 1021 2349616
Sedation 56.14 33.59 28 7420 3334 2347303
Fluid retention 55.79 33.59 36 7412 7010 2343627
Rheumatoid arthritis 55.37 33.59 54 7394 19086 2331551
Rhabdomyolysis 54.93 33.59 35 7413 6669 2343968
Partial seizures 54.91 33.59 19 7429 893 2349744
Euphoric mood 54.73 33.59 19 7429 902 2349735
Restless legs syndrome 53.56 33.59 24 7424 2247 2348390
Therapy non-responder 53.55 33.59 37 7411 8067 2342570
Brain oedema 53.17 33.59 24 7424 2286 2348351
Contraindicated product administered 52.93 33.59 26 7422 2995 2347642
Drug dependence 52.74 33.59 26 7422 3019 2347618
Central nervous system necrosis 52.38 33.59 10 7438 35 2350602
Incorrect route of product administration 51.69 33.59 31 7417 5305 2345332
Purpura senile 51.47 33.59 9 7439 16 2350621
Apathy 51.19 33.59 20 7428 1327 2349310
Tongue biting 51.08 33.59 14 7434 297 2350340
Psychomotor hyperactivity 50.78 33.59 22 7426 1900 2348737
Apnoea 50.29 33.59 20 7428 1391 2349246
Hot flush 50.24 33.59 34 7414 7165 2343472
Haemodynamic instability 50.15 33.59 19 7429 1160 2349477
Dysgeusia 49.82 33.59 36 7412 8423 2342214
Blood pressure decreased 49.20 33.59 37 7411 9199 2341438
Parkinsonism 49.04 33.59 20 7428 1485 2349152
Weight decreased 48.92 33.59 61 7387 28310 2322327
Sleep disorder 48.54 33.59 32 7416 6457 2344180
Acute lung injury 47.69 33.59 12 7436 180 2350457
Tachypnoea 47.66 33.59 22 7426 2207 2348430
Hunger 47.45 33.59 16 7432 695 2349942
Drug screen positive 47.13 33.59 17 7431 903 2349734
Tearfulness 46.81 33.59 17 7431 921 2349716
Bruxism 46.63 33.59 16 7432 733 2349904
Erythema 46.45 33.59 56 7392 25103 2325534
Hypoxic-ischaemic encephalopathy 46.15 33.59 16 7432 756 2349881
Sopor 46.09 33.59 26 7422 3969 2346668
Paraesthesia 45.49 33.59 52 7396 22036 2328601
Alanine aminotransferase increased 45.16 33.59 42 7406 13990 2336647
Back pain 45.15 33.59 62 7386 31597 2319040
Gaze palsy 44.60 33.59 13 7435 347 2350290
Thinking abnormal 44.14 33.59 20 7428 1922 2348715
Cardiomyopathy acute 44.07 33.59 9 7439 48 2350589
Choreoathetosis 43.72 33.59 11 7437 165 2350472
Visual impairment 43.37 33.59 38 7410 11717 2338920
Angioedema 43.32 33.59 33 7415 8363 2342274
Acute kidney injury 43.03 33.59 57 7391 28065 2322572
Transaminases increased 42.76 33.59 26 7422 4561 2346076
Mania 42.75 33.59 21 7427 2419 2348218
Compartment syndrome 42.62 33.59 13 7435 407 2350230
Blood creatine phosphokinase increased 42.53 33.59 27 7421 5109 2345528
Mood swings 42.45 33.59 23 7425 3246 2347391
Accidental poisoning 42.19 33.59 10 7438 115 2350522
Foetal exposure during pregnancy 41.98 33.59 27 7421 5225 2345412
Treatment noncompliance 40.69 33.59 27 7421 5507 2345130
Tarsal tunnel syndrome 40.48 33.59 8 7440 35 2350602
Muscle twitching 40.26 33.59 21 7427 2744 2347893
Epilepsy 39.95 33.59 25 7423 4614 2346023
Nightmare 39.80 33.59 23 7425 3674 2346963
Mucosal dryness 39.74 33.59 12 7436 363 2350274
Upper respiratory tract infection 39.64 33.59 32 7416 8819 2341818
Affect lability 39.56 33.59 19 7429 2083 2348554
Sinus bradycardia 39.44 33.59 19 7429 2097 2348540
Speech disorder 39.18 33.59 28 7420 6436 2344201
Flushing 39.10 33.59 36 7412 11835 2338802
Sympathomimetic effect 38.86 33.59 7 7441 16 2350621
Hyperacusis 38.71 33.59 12 7436 397 2350240
Night sweats 38.28 33.59 22 7426 3478 2347159
Product quality issue 37.94 33.59 34 7414 10795 2339842
Acidosis 37.92 33.59 17 7431 1593 2349044
Accidental exposure to product by child 37.83 33.59 13 7435 598 2350039
Intentional self-injury 37.46 33.59 23 7425 4104 2346533
Aspartate aminotransferase increased 37.24 33.59 36 7412 12576 2338061
Anaphylactic reaction 37.06 33.59 32 7416 9673 2340964
Adrenergic syndrome 36.80 33.59 6 7442 5 2350632
Dysphemia 36.75 33.59 12 7436 471 2350166
Neuroleptic malignant syndrome 36.73 33.59 18 7430 2062 2348575
Impaired work ability 36.02 33.59 17 7431 1793 2348844
Emotional disorder 35.95 33.59 18 7430 2159 2348478
Ventricular fibrillation 35.77 33.59 18 7430 2183 2348454
Miosis 35.61 33.59 15 7433 1209 2349428
Nicotine dependence 35.28 33.59 9 7439 143 2350494
Lymphadenopathy 35.27 33.59 25 7423 5673 2344964
Stress 35.19 33.59 27 7421 6911 2343726
Choroidal effusion 35.17 33.59 9 7439 145 2350492
Lip swelling 34.19 33.59 23 7425 4798 2345839
Electrocardiogram QRS complex shortened 33.83 33.59 8 7440 91 2350546
Chronic fatigue syndrome 33.82 33.59 9 7439 170 2350467
Cerebral venous thrombosis 33.80 33.59 11 7437 427 2350210
Altered state of consciousness 33.73 33.59 21 7427 3839 2346798

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 5171.30 42.43 1198 3162 15114 1727307
Toxicity to various agents 2267.43 42.43 716 3644 28425 1713996
Drug abuse 813.69 42.43 278 4082 13411 1729010
Cardio-respiratory arrest 724.87 42.43 232 4128 9061 1733360
Intentional overdose 721.44 42.43 221 4139 7449 1734972
Seizure 690.78 42.43 274 4086 20167 1722254
Serotonin syndrome 635.26 42.43 161 4199 2627 1739794
Overdose 574.15 42.43 227 4133 16474 1725947
Poisoning 506.99 42.43 132 4228 2400 1740021
Depression 464.20 42.43 195 4165 16474 1725947
Cardiac arrest 395.72 42.43 172 4188 15758 1726663
Agitation 360.79 42.43 145 4215 10881 1731540
Anxiety 351.05 42.43 157 4203 15370 1727051
Generalised tonic-clonic seizure 338.86 42.43 107 4253 3939 1738482
Respiratory arrest 327.15 42.43 114 4246 5725 1736696
Suicidal ideation 324.05 42.43 125 4235 8393 1734028
Status epilepticus 279.45 42.43 79 4281 1967 1740454
Drug interaction 255.94 42.43 154 4206 27804 1714617
Suicide attempt 251.21 42.43 100 4260 7281 1735140
Tremor 225.63 42.43 110 4250 13021 1729400
Intentional product misuse 213.70 42.43 89 4271 7269 1735152
Tachycardia 193.78 42.43 98 4262 12530 1729891
Insomnia 192.19 42.43 106 4254 16170 1726251
Hallucination 182.11 42.43 82 4278 8088 1734333
Electrocardiogram QRS complex prolonged 177.20 42.43 45 4315 730 1741691
Psychotic disorder 170.10 42.43 68 4292 4988 1737433
Drug ineffective 165.29 42.43 166 4194 63635 1678786
Delirium 164.83 42.43 71 4289 6291 1736130
Irritability 160.80 42.43 67 4293 5465 1736956
Aggression 157.49 42.43 74 4286 8041 1734380
Electrocardiogram QT prolonged 147.29 42.43 63 4297 5482 1736939
Depressed level of consciousness 143.13 42.43 65 4295 6527 1735894
Drug hypersensitivity 142.20 42.43 85 4275 15050 1727371
Exposure via ingestion 138.42 42.43 36 4324 644 1741777
Postmortem blood drug level increased 135.35 42.43 22 4338 19 1742402
Confusional state 131.94 42.43 92 4268 21186 1721235
Product substitution issue 130.97 42.43 50 4310 3236 1739185
Hypotension 129.81 42.43 104 4256 29550 1712871
Feeling abnormal 124.16 42.43 70 4290 11096 1731325
Dizziness 114.45 42.43 103 4257 34258 1708163
Unresponsive to stimuli 114.40 42.43 50 4310 4579 1737842
Condition aggravated 107.26 42.43 81 4279 21069 1721352
Mental status changes 104.40 42.43 51 4309 6024 1736397
Myoclonus 102.61 42.43 38 4322 2257 1740164
Disturbance in attention 102.23 42.43 45 4315 4189 1738232
Foetal exposure during pregnancy 102.19 42.43 51 4309 6308 1736113
Hyperhidrosis 99.03 42.43 63 4297 12425 1729996
Death 98.88 42.43 150 4210 87293 1655128
Loss of consciousness 96.04 42.43 66 4294 14809 1727612
Euphoric mood 94.65 42.43 28 4332 817 1741604
Product complaint 92.45 42.43 36 4324 2454 1739967
Paranoia 89.80 42.43 34 4326 2147 1740274
Urticaria 87.82 42.43 58 4302 12183 1730238
Hallucination, visual 80.67 42.43 33 4327 2559 1739862
Restlessness 79.42 42.43 38 4322 4283 1738138
Headache 76.90 42.43 83 4277 34293 1708128
Intentional self-injury 76.32 42.43 32 4328 2641 1739780
Mania 76.22 42.43 30 4330 2103 1740318
Incorrect route of product administration 74.60 42.43 34 4326 3431 1738990
Mydriasis 74.51 42.43 26 4334 1298 1741123
Disorientation 73.77 42.43 39 4321 5430 1736991
Vein of Galen aneurysmal malformation 73.55 42.43 11 4349 1 1742420
Cardiogenic shock 72.15 42.43 30 4330 2424 1739997
Abnormal behaviour 71.06 42.43 40 4320 6302 1736119
Therapeutic response unexpected 69.14 42.43 29 4331 2395 1740026
Accidental overdose 68.64 42.43 34 4326 4130 1738291
Coma 68.61 42.43 41 4319 7221 1735200
Nausea 68.01 42.43 95 4265 51101 1691320
Delusion 64.67 42.43 27 4333 2204 1740217
Sinus tachycardia 64.63 42.43 28 4332 2504 1739917
Memory impairment 63.94 42.43 38 4322 6625 1735796
Hyperreflexia 62.71 42.43 19 4341 602 1741819
Urinary incontinence 62.54 42.43 28 4332 2708 1739713
Pneumonia aspiration 61.12 42.43 34 4326 5232 1737189
Poisoning deliberate 61.03 42.43 20 4340 822 1741599
Anger 56.87 42.43 26 4334 2640 1739781
Autonomic nervous system imbalance 56.01 42.43 16 4344 411 1742010
Panic attack 55.65 42.43 23 4337 1829 1740592
Somnolence 55.18 42.43 50 4310 16689 1725732
Rhabdomyolysis 55.05 42.43 42 4318 11048 1731373
Hallucinations, mixed 53.70 42.43 16 4344 478 1741943
Sleep disorder 52.03 42.43 28 4332 4035 1738386
Major depression 51.93 42.43 17 4343 696 1741725
Fall 51.01 42.43 60 4300 27154 1715267
Clonus 50.06 42.43 15 4345 457 1741964
Social avoidant behaviour 49.65 42.43 16 4344 623 1741798
Tinnitus 49.44 42.43 25 4335 3170 1739251
Exposure during pregnancy 49.40 42.43 24 4336 2793 1739628
Dyskinesia 48.01 42.43 26 4334 3793 1738628
Hypomania 47.64 42.43 15 4345 541 1741880
Dysarthria 45.31 42.43 28 4332 5231 1737190
Atrial septal defect 44.68 42.43 18 4342 1340 1741081
Amnesia 44.59 42.43 27 4333 4864 1737557
Hallucination, auditory 43.13 42.43 20 4340 2097 1740324
Sexual dysfunction 42.76 42.43 19 4341 1804 1740617
Substance abuse 42.59 42.43 16 4344 987 1741434
Small for dates baby 42.44 42.43 14 4346 587 1741834

Pharmacologic Action:

SourceCodeDescription
ATC A08AA62 ALIMENTARY TRACT AND METABOLISM
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
Centrally acting antiobesity products
ATC N06AX12 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
FDA EPC N0000180855 Aminoketone
FDA PE N0000009282 Increased Dopamine Activity
FDA PE N0000009456 Increased Norepinephrine Activity
FDA MoA N0000000102 Norepinephrine Uptake Inhibitors
CHEBI has role CHEBI:35469 antidepressant
MeSH PA D000928 Antidepressive Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D002491 Central Nervous System Agents
MeSH PA D065690 Cytochrome P-450 CYP2D6 Inhibitors
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D015259 Dopamine Agents
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065606 Metabolic Side Effects of Drugs and Substances
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D000077444 Smoking Cessation Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Depressive disorder indication 35489007
Nicotine dependence indication 56294008 DOID:0050742
Seasonal affective disorder indication 247803002
Major depressive disorder indication 370143000
Smoking cessation assistance indication 384742004
Obesity indication 414916001 DOID:9970
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Attention deficit hyperactivity disorder off-label use 406506008
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Mood swings contraindication 18963009
Lowered convulsive threshold contraindication 19260006
Cirrhosis of liver contraindication 19943007 DOID:5082
Myocardial infarction contraindication 22298006 DOID:5844
Feeling agitated contraindication 24199005
Hypertensive disorder contraindication 38341003 DOID:10763
Anorexia nervosa contraindication 56882008 DOID:8689
Hepatic failure contraindication 59927004
Psychotic disorder contraindication 69322001
Opioid dependence contraindication 75544000 DOID:2559
Bulimia nervosa contraindication 78004001
Hostile behavior contraindication 79351003
Injury of head contraindication 82271004
Weight loss contraindication 89362005
Kidney disease contraindication 90708001 DOID:557
Secondary malignant neoplasm of cerebrum contraindication 94248000
Neoplasm of central nervous system contraindication 126951006 DOID:3620
Seizure disorder contraindication 128613002
Bipolar affective disorder, current episode manic contraindication 191618007
Disease of liver contraindication 235856003 DOID:409
Diabetic - poor control contraindication 268519009
Alcohol withdrawal-induced convulsion contraindication 308742005
Panic disorder contraindication 371631005 DOID:594
Sedative Drug Dependence contraindication
Seizure due to Abrupt Benzodiazepine Withdrawal contraindication
Stimulant Drug Dependence contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.87 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 7462626 July 20, 2024 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 8815889 July 20, 2024 FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
174MG APLENZIN VALEANT PHARMS NORTH N022108 April 23, 2008 RX TABLET, EXTENDED RELEASE ORAL 7569610 June 27, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
348MG APLENZIN VALEANT PHARMS NORTH N022108 April 23, 2008 RX TABLET, EXTENDED RELEASE ORAL 7569610 June 27, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
522MG APLENZIN VALEANT PHARMS NORTH N022108 April 23, 2008 RX TABLET, EXTENDED RELEASE ORAL 7569610 June 27, 2026 TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 9107837 June 4, 2027 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 10307376 Nov. 8, 2027 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 8318788 Nov. 8, 2027 USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 8722085 Nov. 8, 2027 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 9125868 Nov. 8, 2027 USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 8916195 Feb. 2, 2030 USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 9248123 Jan. 13, 2032 USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
90MG CONTRAVE NALPROPION N200063 Sept. 10, 2014 RX TABLET, EXTENDED RELEASE ORAL 10231964 July 2, 2034 FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent noradrenaline transporter Transporter INHIBITOR Ki 5.16 CHEMBL CHEMBL
Sodium-dependent dopamine transporter Transporter INHIBITOR Kd 6.28 WOMBAT-PK CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel IC50 4.30 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel IC50 6 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel IC50 5.74 CHEMBL
Sodium-dependent serotonin transporter Transporter Kd 5.04 WOMBAT-PK
Cytochrome P450 2D6 Enzyme WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 4.80 PDSP
Cytochrome P450 2C19 Enzyme IC50 5.70 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.85 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter IC50 5.91 CHEMBL

External reference:

IDSource
4019645 VUID
N0000147738 NUI
C0085208 UMLSCUI
D00817 KEGG_DRUG
01ZG3TPX31 UNII
3562 INN_ID
96199001 SNOMEDCT_US
4019645 VANDF
42347 RXNORM
004611 NDDF
387564004 SNOMEDCT_US
d00181 MMSL
444 PUBCHEM_CID
CHEBI:3219 CHEBI
CHEMBL894 ChEMBL_ID
CHEMBL1698 ChEMBL_ID
905818-69-1 SECONDARY_CAS_RN
DB01156 DRUGBANK_ID
7135 IUPHAR_LIGAND_ID
CHEMBL1201735 ChEMBL_ID
D016642 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-5445 TABLET, FILM COATED, EXTENDED RELEASE 200 mg ORAL ANDA 20 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0115-6811 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 19 sections
WELLBUTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0173-0135 TABLET, FILM COATED 150 mg ORAL NDA 19 sections
WELLBUTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0173-0722 TABLET, FILM COATED 200 mg ORAL NDA 19 sections
WELLBUTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0173-0947 TABLET, FILM COATED 100 mg ORAL NDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0410 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-0415 TABLET, EXTENDED RELEASE 150 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0185-1111 TABLET, EXTENDED RELEASE 200 mg ORAL ANDA 19 sections
WELLBUTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0187-0730 TABLET, EXTENDED RELEASE 150 mg ORAL NDA 19 sections
WELLBUTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0187-0731 TABLET, EXTENDED RELEASE 300 mg ORAL NDA 19 sections
Aplenzin HUMAN PRESCRIPTION DRUG LABEL 1 0187-5810 TABLET, EXTENDED RELEASE 174 mg ORAL NDA 20 sections
Aplenzin HUMAN PRESCRIPTION DRUG LABEL 1 0187-5811 TABLET, EXTENDED RELEASE 348 mg ORAL NDA 20 sections
Aplenzin HUMAN PRESCRIPTION DRUG LABEL 1 0187-5812 TABLET, EXTENDED RELEASE 522 mg ORAL NDA 20 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0433 TABLET, FILM COATED 75 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0435 TABLET, FILM COATED 100 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-7200 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 16 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3331 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3540 TABLET, FILM COATED, EXTENDED RELEASE 100 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3541 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3542 TABLET, FILM COATED, EXTENDED RELEASE 200 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-3543 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 19 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-5535 TABLET, FILM COATED 100 mg ORAL ANDA 15 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-5554 TABLET, FILM COATED 75 mg ORAL ANDA 15 sections
BuPROPion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-6553 TABLET, EXTENDED RELEASE 150 mg ORAL ANDA 14 sections
BuPROPion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-6561 TABLET, EXTENDED RELEASE 100 mg ORAL ANDA 14 sections
BUDEPRION XL HUMAN PRESCRIPTION DRUG LABEL 1 0615-7560 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 16 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7631 TABLET, FILM COATED 75 mg ORAL ANDA 14 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7632 TABLET, FILM COATED 100 mg ORAL ANDA 14 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7659 TABLET, FILM COATED, EXTENDED RELEASE 100 mg ORAL ANDA 16 sections
Bupropion Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7660 TABLET, FILM COATED, EXTENDED RELEASE 150 mg ORAL ANDA 16 sections